PSN 043
Natural health product licensed in Canada
- Licence holder
- Veevance Inc.
- NPN or DIN-HM
- 80002175
- Status
- Inactive licence
- Licence date
- 5 October 2006
- Revision date
- 6 July 2021
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Source : Fruit(s) Extraction ratio : 4:1 Dry plant equivalent : 500 mg | 125 mg | Not calculated |
Non-medicinal ingredients
Gélatine, Stéarate de magnésium, Cellulose - microcrystalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Hommes | minimum: 19 years | 1 Capsule | 3 Tous les jours |
Uses authorised in Canada
Utilisé en phytothérapie pour aider à soulager les symptômes urologiques (e.g. diminution de l'écoulement de l'urine, miction incomplète, polyuries nocturnes et diurnes) associés à l'hypertrophie bénigne de la prostate, légère à modérée.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consulter un praticien de soins de santé si les symptômes persistent ou s'aggravent. Consulter un praticien de soins de santé avant d'en faire l'usage afin d'exclure un diagnostique du cancer de la prostate.
Source
Official Health Canada record, licence 80002175
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2021. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.